| Prevention of a first myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 11304891 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Coronary heart disease is the leading cause of morbidity and mortality in men and women in the Western world. We now have significant evidence that prevention of the first coronary event using lifestyle and pharmacologic therapies is paramount. Events are caused by inflamed arteries leading to rupture of atherosclerotic plaques that induce potentially occlusive thrombi. Analysis of event reduction trials has revealed that LDL-C lowering is only one part of the therapy needed to stabilize plaque. HMG-Co-A-reductase inhibitors, fibrates, and statins all have differing mechanisms of action that provide not only lipid but also inflammatory, rheologic, and coagulation benefits. Concentration and sizes of lipoprotein subfractions have emerged as important new tools with small dense LDL particles having more atherogenicity, which has led to an increasing use of aggressive combination therapy for prevention of first myocardial infarction. Proper use of lipid-lowering therapies requires knowledge of drug metabolism drug-drug interactions. |
| | |
Authors:
|
T D Dayspring |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 41 ISSN: 0091-2700 ISO Abbreviation: J Clin Pharmacol Publication Date: 2001 Apr |
Date Detail:
|
Created Date: 2001-04-17 Completed Date: 2001-09-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 359-67 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
analysis Cholesterol, LDL / analysis Drug Therapy, Combination Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology, therapeutic use Hypercholesterolemia / prevention & control*, therapy Inflammation / drug therapy Myocardial Infarction / etiology, prevention & control*, therapy Risk Factors Thrombosis / prevention & control Vasodilation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New diagnostic criteria for the neuropsychiatric form of systemic lupus erythematosus
Next Document: Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need f...